<DOC>
	<DOC>NCT00813774</DOC>
	<brief_summary>To compare the bioavailability of a single dose of certolizumab pegol solutions given subcutaneously either by one of the three formulations and to investigate safety and tolerability.</brief_summary>
	<brief_title>Bio-availability Comparison of Three Formulations of Certolizumab Pegol in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Healthy male and female volunteers aged between 18 and 55 Body Mass Index (BMI) between 18 and 30 kg/m2 with normal laboratory data negative for Tuberculosis test normal Electrocardiogram (ECG) adequate contraception for females given informed consent Any significant abnormality in medical history, physical examination, laboratory testing Intake of concomitant medication smoking more than 10 cigarettes per day alcohol or drug abuse pregnancy or breast feeding history of tuberculosis participation in another trial within 3 months prior to this study previous administration of certolizumab pegol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Cimzia</keyword>
	<keyword>certolizumab pegol</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Healthy volunteers</keyword>
</DOC>